A
Algisys
Algisys produces algal oils and high protein additives for the supplement, food, beverage, pharmaceutical and animal feed markets
About Algisys
AlgiSys is a biotechnology startup that specializes in the production of high-quality Omega-3 Algal EPA (EicosaPentaenoic Acid) using proprietary strains of algae. The company operates in the multi-billion dollar omega-3 fatty acids market, which has a high demand for EPA and DHA (DocosaHexaenoic Acid), two of the most beneficial forms of omega-3 fatty acids.
AlgiSys's business model revolves around the production of all-natural EPA Omega-3 nutritional oils and high protein vegan biomass. The company's target clients are primarily in the health and wellness sector, which includes individuals and businesses interested in nutritional supplements and vegan protein sources.
The company's unique selling point is its proprietary microalgae, which are heterotrophic producers of EPA. This means they can grow quickly in the dark using fermentation technology. By employing traditional industrial fermentation equipment, AlgiSys can efficiently scale and accelerate the microalgae's natural oil production time to just a few days at commercial levels.
AlgiSys has developed the first commercial algal EPA production process to cost-effectively produce this important omega-3 fatty acid. The company aims to play a significant role in meeting the rapidly growing demand for EPA and high protein biomass products using its exclusive biotechnology.
In summary, AlgiSys is a biotech startup that leverages proprietary technology to produce high-quality Omega-3 Algal EPA and high protein vegan biomass, targeting the health and wellness market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Edinburgh, United Kingdom
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 74.7/100
- Industry
- Health, Wellness Beauty
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Algae, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2021 | $45M | $180M | The Peakstone Group | — |
| SERIES AOther financing | Aug 2013 | $6.2M | $25M | Undisclosed | — |
Growth signals
Latest recorded traffic for Algisys is 390 monthly website visits, down 72.1% over the last three months. Algisys's team grew 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
The Peakstone Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Algisys on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Algisys’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







